Genitourinary Cancers

Wenxin Xu, MD, discusses future considerations for the treatment of patients with kidney cancer. 

Before closing out their review of mainstay combination therapy in the first-line setting of advanced clear cell RCC, panelists reflect on available quality of life data.

Focused discussion on brain metastases or sarcomatoid disease in advanced clear cell RCC and the selection of first-line treatment regimens.

Patients with non–clear cell renal cell carcinoma and sarcomatoid differentiation experience inferior outcomes to standard systemic therapy compared with those with clear cell disease.

The combination of nivolumab and ipilimumab (Yervoy) was associated with worse clinical benefit in patients with metastatic clear cell renal cell carcinoma who have low serum iron compared with patients with normal/high serum iron.

Tivozanib demonstrated an improvement in overall survival compared with sorafenib in pretreated patients with advanced clear cell renal cell carcinoma, particularly in those who remained progression-free at 1 year and beyond.

Toni K. Choueiri, MD, provides perspective on key research in renal cell carcinoma, including the first demonstration of benefit with triplet therapy in metastatic clear cell disease, the expansion of HIF-2α inhibition into the first line, and success with VEGF/immune-oncology approaches in the non–clear cell population.

Shared insight on the importance of sites of metastases and how they may impact first-line treatment selection in advanced clear cell RCC.

Centering conversation on systemic therapy, panelists review trial data behind the first-line combination regimens for patients with advanced clear cell RCC.

Comprehensive insight to the role of nephrectomy over systemic therapy in patients who receive a diagnosis of advanced clear cell RCC.

Expert oncologists open their discussion on advanced clear cell RCC by identifying its prevalence and prognoses before moving into treatment considerations.

The FDA has approved bevacizumab-adcd, a bevacizumab biosimilar, for the treatment of six types of cancer.

Nicholas J. Vogelzang, MD, a world-renowned genitourinary oncologist and investigator and the 2018 Giants of Cancer Care® award winner in GU cancer, died on September 20, 2022. He was 72.

OncLive® will be LIVE with OncLive® News Network: On Location at the 2022 ESMO Congress. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

The triplet regimen of cabozantinib plus standard-of-care nivolumab and ipilimumab reduced the risk of disease progression or death by 27% vs placebo in patients with advanced renal cell carcinoma.

The combination of adjuvant nivolumab and ipilimumab did not elicit a significant disease-free survival benefit vs placebo in patients with localized, renal cell carcinoma at high risk for relapse after nephrectomy.

Treatment with atezolizumab did not improve clinical outcomes vs placebo following resection in patients with renal cell carcinoma at increased risk of recurrence.

Perioperative nivolumab did not improve recurrence-free survival compared with surgery alone in patients with renal cell carcinoma.

Moshe Ornstein, MD, MA, discusses toxicity concerns when treating renal cell carcinoma.

Eric Jonasch, MD, discusses the best patient population when treating with belzutifan in clear cell renal cell carcinoma.

Kathryn E. Beckermann, MD, PhD, discusses the evolving adjuvant treatment setting for renal cell carcinoma.

Toni Choueiri, MD, discusses the future examination of adjuvant pembrolizumab in renal cell carcinoma.

Amir Goldkorn, MD, discusses the methods utilized to predict chemotherapy benefit in bladder cancer.

Successful, established immunotherapies that have been approved for use in the metastatic setting are rapidly moving forward into the adjuvant and neoadjuvant settings, and novel agents are emerging in later lines.

Kathryn E. Beckermann, MD, PhD, discusses the future of treatment in renal cell carcinoma.

Eric Jonasch, MD, discusses the efficacy and safety of belzutifan observed in the LITESPARK-001 trial for patients with advanced clear cell RCC and the next steps for investigating belzutifan in this patient population.

Eric Jonasch, MD, discusses the future of belzutifan (Welireg) in clear cell renal cell carcinoma.

Kathryn E. Beckermann, MD, PhD, discusses the need for biomarkers in frontline renal cell carcinoma.

The Kidney Cancer Treatment guidelines, housed within the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology, have been revised, granting tivozanib Category 1 status as a subsequent therapy for patients with renal cell carcinoma who have received at least 2 prior lines of treatment.

The combination of nivolumab and ipilimumab failed to elicit a statistically significant improvement in disease-free survival compared with placebo as adjuvant treatment in patients with localized renal cell carcinoma who had undergone a full or partial removal of the kidney and were at moderate or high risk of relapse, failing to meet the primary end point of part A of the phase 3 CheckMate-914 trial.